ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2022
GOTHENBURG, Sweden, Aug. 3, 2022 /PRNewswire/ -- Zinzino group revenue increased with a total of 10%, compared with the previous year.
The revenue in July for Zinzino's sales markets increased by 10% and amounted to SEK 105.9 (96.6) million. Faun Pharma's external sales increased by 14% and amounted to SEK 3.3 (2.9) million. Overall, the Group increased revenues by 10% to SEK 109.2 (99.5) million compared with the previous year.
Accumulated revenue for January ? July 2022 increased by 2% to SEK 773.1 (755.3) million.
Revenues were distributed as follows:
Regions, mSEK
22-July
21-July
Change
YTD 2022
YTD 2021
Change
The Nordics
26.5
28.6
-7 %
182.6
215.4
-15 %
Central Europe
22.1
17.9
23 %
146.0
125.8
16 %
East Europe
24.4
24.9
-2 %
184.5
185.3
0 %
South & West Europe
12.3
10.8
14 %
87.0
81.3
7 %
The Baltics
5.8
5.4
7 %
40.5
41.0
-1 %
North America
6.3
4.0
58 %
38.9
29.1
34 %
Asia-Pacific
7.6
5.0
52 %
41.9
41.2
2 %
Africa
0.9
0.0
4.1
0.0
Zinzino
105.9
96.6
10 %
725.5
719.1
1 %
Faun Pharma
3.3
2.9
14 %
47.6
36.2
31 %
Zinzino Group
109.2
99.5
10 %
773.1
755.3
2 %
Countries in regions:
The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom, Belgium, Ireland
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA
Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 14:00 the 3rd of August 2022.
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform.
Panda Health...